Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on July 9, 2015. The report details the results of the company's Annual Meeting of Stockholders held on that date. The registrant is a Nevada corporation headquartered in Costa Mesa, California.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes and Corporate Actions
- Shareholder Voting Results: As of the record date (May 1, 2015), 16,265,663 shares were entitled to vote. 9,900,676 shares were present in person or by proxy.
- Director Elections: Shareholders elected five directors for a one-year term: John B. Hollister, Cosmas N. Lykos, Gerald W. McLaughlin, Thomas A. George, and Douglas S. Ingram. All nominees received 9,323,141 votes "For" with only 310 votes "Withheld."
- Accounting Firm Ratification: The selection of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2015, was ratified with 9,900,426 votes "For" and zero votes "Against."
- Compensation Plan Approval: Shareholders approved the Nemus Bioscience, Inc. 2014 Omnibus Incentive Plan (the "2014 Plan").
Guidance, Outlook, and Equity Plan Details
Management commentary regarding future financial guidance or operational outlook is not included in this filing. However, specific details regarding the approved 2014 Omnibus Incentive Plan were disclosed:
- Total Authorized Shares: 3,200,000 shares of common stock.
- Shares Subject to Options: 1,810,000 shares as of July 9, 2015.
- Shares Available for Issuance: 1,390,000 shares remained available under the plan.
Key Facts for Investor Verification
- Verify the company name is Nemus Bioscience, Inc., as the input metadata referenced Skye Bioscience, Inc.
- Confirm the 1,390,000 shares remaining available under the 2014 Omnibus Incentive Plan for potential dilution analysis.
- Note the high level of shareholder support for the board of directors and the compensation plan (over 99% approval on voted shares).
- Review the definitive proxy statement (Schedule 14A) filed on June 10, 2015, for the full terms of the 2014 Plan.